Erratum: High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens (Psychopharmacology DOI 10.1007/s00213-012-2680-6);High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens

Psychopharmacology

Volumn 223, Issue 1, 2012, Pages 1-15

  Reissig, Chad J ^a   Carter, Lawrence P ^b   Johnson, Matthew W ^a   Mintzer, Miriam Z ^a   Klinedinst, Margaret A ^a   Griffiths, Roland R ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Dextromethorphan; Dose effects; Drug abuse; Entheogen; Hallucinogen; Humans; Mystical experience; Psychedelic; Subjective effects; Triazolam

Indexed keywords

DEXTROMETHORPHAN; PLACEBO; PSILOCYBINE; PSYCHEDELIC AGENT; TRIAZOLAM;

ADULT; BEHAVIOR CHANGE; CONSCIOUSNESS LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEART RATE; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; MALE; MOOD CHANGE; NORMAL HUMAN; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; PSYCHOMOTOR PERFORMANCE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; URINALYSIS; VOMITING;

EID: 84859515151     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-013-3172-z     Document Type: Erratum

References (60)

1. Addy PH (2012) Acute and post-acute behavioral and psychological effects of Salvinorin A in humans. Psychopharmacology (Berl) 220:195-204
2. Aghajanian GK, Marek GJ (1999) Serotonin and hallucinogens. Neuropsychopharmacology 21:16S-23S (Pubitemid 29396466)
3. Banken JA, Foster H (2008) Dextromethorphan. Ann N Y Acad Sci 1139:402-411
4. Barnhart JW (1980) The urinary excretion of dextromethorphan and three metabolites in dogs and humans. Toxicol Appl Pharmacol 55:43-48 (Pubitemid 10036689)
5. Bem JL, Peck R (1992) Dextromethorphan. An overview of safety issues. Drug Saf 7:190-199
6. Bobo WV, Miller SC, Martin BD (2005) The abuse liability of dextromethorphan among adolescents: a review. J Child Adolesc Subst Abuse 14(4):55-75 (Pubitemid 41480617)
7. Boyer EW (2004) Dextromethorphan abuse. Pediatr Emerg Care 20:858-863 (Pubitemid 40039880)
8. Bryner JK, Wang UK, Hui JW, Bedodo M, MacDougall C, Anderson IB (2006) Dextromethorphan abuse in adolescence: an increasing trend: 1999-2004. Arch Pediatr Adolesc Med 160:1217-1222 (Pubitemid 44901683)
9. Carter LP, Richards BD, Mintzer MZ, Griffiths RR (2006) Relative abuse liability of GHB in humans: a comparison of psychomotor, subjective, and cognitive effects of supratherapeutic doses of triazolam, pentobarbital, and GHB. Neuropsychopharmacology 31:2537-2551 (Pubitemid 44607073)
10. Carter LP, Griffiths RR, Mintzer MZ (2009) Cognitive, psychomotor, and subjective effects of sodium oxybate and triazolam in healthy volunteers. Psychopharmacology (Berl) 206:141-154
11. Church J (1990) Dextromethorphan, dysphoria and NMDA receptors. Neuromodulatory effects of dextromethorphan: role of NMDA receptors in responses. Trends Pharmacol Sci 11:146-147 (Pubitemid 20118005)
12. Church J, Sawyer D, McLarnon JG (1994) Interactions of dextromethorphan with the N-methyl-D-aspartate receptor-channel complex: single channel recordings. Brain Res 666:189-194 (Pubitemid 24369030)
13. Falck R, Li L, Carlson R, Wang J (2006) The prevalence of dextromethorphan abuse among high school students. Pediatrics 118:2267-2269
14. Fantegrossi WE, Murnane KS, Reissig CJ (2008) The behavioral pharmacology of hallucinogens. Biochem Pharmacol 75:17-33 (Pubitemid 350235393)
15. Forrester MB (2011) Dextromethorphan abuse in Texas, 2000-2009. J Addict Dis 30:243-247
16. Franklin PH, Murray TF (1992) High affinity [3H]dextrorphan binding in rat brain is localized to a noncompetitive antagonist site of the activated N-methyl-D-aspartate receptor-cation channel. Mol Pharmacol 41:134-146
17. Fribourg M, Moreno JL, Holloway T et al (2011) Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs. Cell 147:1011-1023
18. Gouzoulis-Mayfrank E, Thelen B, Habermeyer E, Kunert HJ, Kovar KA, Lindenblatt H, Hermle L, Spitzer M, Sass H (1999) Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers. Results of an experimental double-blind placebo-controlled study. Psychopharmacology (Berl) 142:41-50 (Pubitemid 29196062)
19. Griffiths RR, Johnson MW (2005) Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds. J Clin Psychiatry 66(Suppl 9):31-41 (Pubitemid 43011561)
20. Griffiths RR, Richards WA, McCann U, Jesse R (2006) Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl) 187:268-28
21. Griffiths RR, Johnson MW, Richards WA, Richards BD, McCann U, Jesse R (2011) Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology (Berl) 218:649-665
22. Holtzman SG (1982) Phencyclidine-like discriminative stimulus properties of opioids in the squirrel monkey. Psychopharmacology (Berl) 77:295-300 (Pubitemid 12061689)
23. Holtzman SG (1994) Discriminative stimulus effects of dextromethorphan in the rat. Psychopharmacology (Berl) 116:249-254 (Pubitemid 24345273)
24. Hood RW Jr, Hill PC, Spilka B (2009) The psychology of religion: an empirical approach, 4th edn. Guilford, New York
25. Johanson CE, Kilbey M, Gatchalian K, Tancer M (2006) Discriminative stimulus effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans trained to discriminate among d-amphetamine, meta-chlorophenylpiperazine and placebo. Drug Alcohol Depend 81:27-36 (Pubitemid 41682476)
26. Johnson M, Richards W, Griffiths R (2008) Human hallucinogen research: guidelines for safety. J Psychopharmacol 22:603-620
27. Lofwall MR, Griffiths RR, Mintzer MZ (2006) Cognitive and subjective acute dose effects of intramuscular ketamine in healthy adults. Exp Clin Psychopharmacol 14:439-449 (Pubitemid 44789965)
28. Metzner R, Litwin G, Weil G (1965) The relation of expectation and mood to psilocybin reactions: a questionnaire study. Psychedelic Rev 5:3-39
29. Mintzer MZ, Griffiths RR (2005) An abuse liability comparison of flunitrazepam and triazolam in sedative drug abusers. Behav Pharmacol 16:579-584 (Pubitemid 41416077)
30. Morris BJ, Cochran SM, Pratt JA (2005) PCP: from pharmacology to modelling schizophrenia. Curr Opin Pharmacol 5:101-106 (Pubitemid 40124542)
31. Mumford GK, Rush CR, Griffiths RR (1995) Abecarnil and alprazolam in humans: behavioral, subjective and reinforcing effects. J Pharmacol Exp Ther 272:570-580
32. Murray TF, Leid ME (1984) Interaction of dextrorotatory opioids with phencyclidine recognition sites in rat brain membranes. Life Sci 34:1899-1911 (Pubitemid 14134646)
33. Newell KA, Zavitsanou K, Huang XF (2007) Short and long term changes in NMDA receptor binding in mouse brain following chronic phencyclidine treatment. J Neural Transm 114:995-1001 (Pubitemid 47106448)
34. Nichols DE (2004) Hallucinogens. Pharmacol Ther 101:131-181 (Pubitemid 38167565)
35. Nicholson KL, Hayes BA, Balster RL (1999) Evaluation of the reinforcing properties and phencyclidine-like discriminative stimulus effects of dextromethorphan and dextrorphan in rats and rhesus monkeys. Psychopharmacology (Berl) 146:49-59 (Pubitemid 29441113)
36. Pahnke WN (1969) Psychedelic drugs and mystical experience. Int Psychiatry Clin 5:149-162
37. Parsons CG, Quack G, Bresink I, Baran L, Przegalinski E, Kostowski W, Krzascik P, Hartmann S, Danysz W (1995) Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo. Neuropharmacology 34:1239-1258
38. Riba J, Rodriguez-Fornells A, Strassman RJ, Barbanoj MJ (2001) Psychometric assessment of the Hallucinogen Rating Scale. Drug Alcohol Depend 62:215-223 (Pubitemid 32276069)
39. Richards WA, Rhead JC, DiLeo FB, Yensen R, Kurland AA (1977) The peak experience variable in DPT-assisted psychotherapy with cancer patients. J Psychedelic Drugs 9:1-10 (Pubitemid 8106580)
40. Romanelli F, Smith KM (2009) Dextromethorphan abuse: clinical effects and management. J Am Pharm Assoc 49:e20-e25
41. Rush CR, Frey JM, Griffiths RR (1999) Zaleplon and triazolam in humans: acute behavioral effects and abuse potential. Psychopharmacology (Berl) 145:39-51 (Pubitemid 29339761)
42. Schmid B, Bircher J, Preisig R, Kupfer A (1985) Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther 38:618-624 (Pubitemid 16124372)
43. Schutz CG, Soyka M (2000) Dextromethorphan challenge in alcohol-dependent patients and controls. Arch Gen Psychiatry 57:291-292 (Pubitemid 30140439)
44. Sinner B, Graf BM (2008) Ketamine. Handb Exp Pharmacol 182:313-333
45. Soyka M, Bondy B, Eisenburg B, Schutz CG (2000) NMDA receptor challenge with dextromethorphan-subjective response, neuroendocrinological findings and possible clinical implications. J Neural Transm 107:701-714 (Pubitemid 30364710)
46. Strassman RJ, Qualls CR, Uhlenhuth EH, Kellner R (1994) Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale. Arch Gen Psychiatry 51:98-108 (Pubitemid 24054311)
47. Tancer ME, Johanson CE (2001) The subjective effects of MDMA and mCPP in moderate MDMA users. Drug Alcohol Depend 65:97-101 (Pubitemid 33063665)
48. Tancer M, Johanson CE (2003) Reinforcing, subjective, and physiological effects of MDMA in humans: a comparison with d-amphetamine and mCPP. Drug Alcohol Depend 72:33-44 (Pubitemid 37255328)
49. Turek IS, Soskin RA, Kurland AA (1974) Methylenedioxyamphetamine (MDA) subjective effects. J Psychedelic Drugs 6:7-14
50. Vengurlekar SS, Heitkamp J, McCush F, Velagaleti PR, Brisson JH, Bramer SL (2002) A sensitive LC-MS/MS assay for the determination of dextromethorphan and metabolites in human urine-application for drug interaction studies assessing potential CYP3A and CYP2D6 inhibition. J Pharm Biomed Anal 30:113-124 (Pubitemid 34876685)
51. Vollenweider FX, Kometer M (2010) The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat Rev Neurosci 11:642-651
52. Werling LL, Keller A, Frank JG, Nuwayhid SJ (2007) A comparison of the binding profiles of dextromethorphan, memantine, fluoxetine and amitriptyline: treatment of involuntary emotional expression disorder. Exp Neurol 207:248-257 (Pubitemid 47429659)
53. Wilson MD, Ferguson RW, Mazer ME, Litovitz TL (2011) Monitoring trends in dextromethorphan abuse using the National Poison Data System: 2000-2010. Clin Toxicol (Phila) 49:409-415
54. Winter JC, Doat M, Rabin RA (2000) Potentiation of DOM-induced stimulus control by non-competitive NMDA antagonists: a link between the glutamatergic and serotonergic hypotheses of schizophrenia. Life Sci 68:337-344
55. Winter JC, Eckler JR, Rice KC, Rabin RA (2005) Serotonergic/glutamatergic interactions: potentiation of phencyclidine-induced stimulus control by citalopram. Pharmacol Biochem Behav 81:694-700 (Pubitemid 40966818)
56. Wolfinger R, Chang M (1995) Comparing the SAS GLM and MIXED procedures for repeated measurements analysis. SUGI Proc 1995:1-11
57. Young AM, Herling S, Winger GD, Woods JH (1981) Comparison of discriminative and reinforcing effects of ketamine and related compounds in the rhesus monkey. NIDA Res Monogr 34:173-179 (Pubitemid 12221648)
58. Zawertailo LA, Kaplan HL, Busto UE, Tyndale RF, Sellers EM (1998) Psychotropic effects of dextromethorphan are altered by the CYP2D6 polymorphism: a pilot study. J Clin Psychopharmacol 18:332-337 (Pubitemid 28353877)
59. Zawertailo LA, Tyndale RF, Busto U, Sellers EM (2010) Effect of metabolic blockade on the psychoactive effects of dextromethorphan. Hum Psychopharmacol 25:71-79
60. Ziaee V, Akbari HE, Hoshmand A, Amini H, Kebriaeizadeh A, Saman K (2005) Side effects of dextromethorphan abuse, a case series. Addict Behav 30:1607-1613 (Pubitemid 41191305)